title: Changes in Pulmonary Function and Controlled Ventilation-High Resolution CT of Chest After Antibiotic Therapy in Infants and Young Children with Cystic Fibrosis.
abstract: BACKGROUND
  Infants with cystic fibrosis (CF) develop early progressive lung disease which may be asymptomatic. Infant pulmonary function tests (IPFT) and controlled ventilation-high resolution computed tomography (CV-HRCT) of chest can detect early asymptomatic lung disease. It is not well established that these objective measures can detect changes in lung disease after clinical interventions.
  
  
  OBJECTIVE
  The purpose of this study was to evaluate usefulness of IPFT and CV-HRCT to detect changes in lung disease after intravenous (IV) antibiotic therapy in infants with early CF-related lung disease.
  
  
  METHODS
  IPFTs and CV-HRCT done before and after 2 weeks of IV antibiotics in infants at our institution over the last 12 years were compared. CV-HRCTs were compared using the modified Brody scoring system.
  
  
  RESULTS
  The sample included 21 infants, mean age 85.2 ± 47.6 weeks. Mean change in weight was 0.4 ± 0.38 kg (p = 0.001). Significant changes in IPFT included mean % predicted FEV(0.5) (+13.5 %, p = 0.043), mean %FEF(25-75) (+30.2 %, p = 0.008), mean %RV/TLC (-11.2 %, p = 0.008), and mean %FRC/TLC (-4.5 %, p = 0.001). Total Brody scores improved from a median of 10 to 5 (p < 0.001) as did mean scores for airway wall thickening (p = 0.050), air trapping (p < 0.001), and parenchymal opacities (p = 0.003).
  
  
  CONCLUSIONS
  IPFT and CV-HRCT can be used as objective measures of improvement in lung disease for infants with CF treated with antibiotics.
authors.affiliation: Departments of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA, Shahid.Sheikh@nationwidechildrens.org.
authors.forename: Shahid I
authors.initials: SI
authors.lastname: Sheikh
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Long
authors.forename: Robert
authors.initials: R
authors.lastname: Flucke
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Ryan-Wenger
authors.forename: Don
authors.initials: D
authors.lastname: Hayes
authors.forename: Karen S
authors.initials: KS
authors.lastname: McCoy
mesh_terms: D061605:Administration, Intravenous; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007223:Infant; D008168:Lung / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000382:microbiology / Q000503:physiopathology; D008297:Male; D009820:Ohio; D011237:Predictive Value of Tests; D020127:Recovery of Function; D012121:Respiration, Artificial / Q000379:methods*; D012129:Respiratory Function Tests; D015656:Respiratory Mechanics; D012141:Respiratory Tract Infections / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D012189:Retrospective Studies; D036542:Tomography, Spiral Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents